• Strafford #1Strafford
    will be offering a webinar/teleconference entitled "AIA Impact on Section 103 and Non-Obviousness:
    Navigating Timing Changes, Post-AIA Treatment of KSR, and Secondary Considerations to Meet Patent Validity
    Requirements" on June 25, 2013 from 1:00 – 2:30 pm (EDT).  Thomas L. Irving and Erika H. Arner of Finnegan
    Henderson Farabow Garrett & Dunner will provide guidance to patent counsel
    regarding the impact of the Leahy-Smith America Invents Act (AIA) on section
    103 and non-obviousness, and offer best practices for meeting the
    non-obviousness requirement for patent validity.  The panel will review the following
    questions:

    • How has the AIA impacted the determination of
    obviousness?
    • How has the Federal Circuit treated the issues of
    non-obviousness?
    • What practices should counsel employ in order to
    meet the non-obviousness requirement?

    The
    registration fee for the webinar is $297 ($362 for registration and CLE processing).  Those interested in registering for the
    webinar, can do so here.

  • By Kevin E. Noonan

    U.S. Trade RepresentativeOn May 1st, Acting U.S. Trade
    Representative (USTR) Demetrius Marantis issued the 2013 Special 301
    Report.  According to the USTR website,
    the Report "demonstrates U.S. resolve to take strong action to
    support critical jobs and exports in IP-intensive industries."  "The actions reflected in this
    year's report send a message to all trading partners on the Priority Watch List
    and the Watch List that the United States is prepared to use the Special 301
    process to its full effect, both to recognize positive action and, where
    necessary and appropriate, to identify deterioration of the IPR protection and
    enforcement systems that play such a vital role in international trade,"
    according to USTR Marantis.  The USTR Report "demonstrates U.S. resolve to take strong action to support critical jobs
    and exports in IP-intensive industries," according to the website
    announcement, and "regrets" the inclusion of Ukraine, which "earned the
    first new Priority Foreign Country designation in 11 years" as the result
    of its "severely deteriorating
    climate for IPR protection and market access," and "call[s] upon that government to
    reverse recent backsliding and swiftly resolve the problems identified" in
    the Report.  This action follows last year's inclusion of Ukraine on the
    Priority Watch List "in light of serious and growing concerns relating to
    counterfeiting and rampant piracy."  On the other hand, the Report hails
    Canada for making "long-awaited
    progress on concerns identified in past reports."

    The Report is promulgated pursuant to
    Section 182 of the Trade Act of 1974, as amended by the Omnibus Trade and
    Competitiveness Act of 1988 and the Uruguay Round Agreements Act (enacted in
    1994).  The Trade Representative is required under the Act to "identify
    those countries that deny adequate and effective protection for IPR or deny
    fair and equitable market access for persons that rely on intellectual property
    protection."  The Trade Representative has implemented these
    provisions by creating a "Priority Watch List" and "Watch List."  Placing a country on the Priority Watch List or Watch List is used to indicate
    that the country exhibits "particular problems . . . with respect to IPR
    protection, enforcement, or market access for persons relying on intellectual
    property."  These watch lists are reserved for countries having "the
    most onerous or egregious acts, policies, or practices and whose acts,
    policies, or practices have the greatest adverse impact (actual or potential)
    on the relevant U.S. products."

    CoverThis Report, on the state of intellectual
    property rights worldwide, identifies ten countries on a "Priority Watch
    List" and another 30 countries on the "Watch List," all relating
    to deficiencies in intellectual property protection in these countries.  The Priority Watch List in the Report lists Algeria, Argentina, Chile, Chine, India,
    Indonesia, Pakistan, Russia, Thailand, and Venezuela, with Canada and Israel
    exiting the list compared with last year's Report.  Countries on this list
    "do not provide an adequate level of IPR protection or enforcement, or
    market access to persons relying on intellectual property protection." 
    On the Watch List this year are Barbados, Belarus, Bolivia, Brazil, Bulgaria,
    Canada, Columbia, Costa Rica, Dominican Republic, Ecuador, Egypt, Finland,
    Greece, Guatemala, Israel, Italy, Jamaica, Kuwait, Lebanon, Mexico, Paraguay, Peru,
    Philippines, Romania, Tajikstan, Trinidad and Tobago, Turkey, Turkmenistan,
    Uzbekistan, and Vietnam; compared to last year, Brunei and Norway have been
    removed from the list and Canada is on the list this year, with Ukraine having
    been moved to the Priority Watch List.  The Report lists a "wide range of concerns, including the continued deterioration in
    IPR protection, enforcement, and market access for persons relying on IPR in
    Ukraine; the growing problem of misappropriation of trade secrets in China and
    elsewhere; troubling 'indigenous innovation' policies that may unfairly
    disadvantage U.S. rights holders in China; the continuing challenges of
    copyright piracy over the Internet in countries such as Brazil, Italy, and
    Russia; and other ongoing, systemic IPR enforcement issues presented in many trading
    partners around the world."  Despite these concerns, the Report
    evinces a desire to "work[] closely with the governments of [U.S.] trading
    partners [identified in the Report] to address both emerging and continuing
    concerns, and to build on the positive results many of these governments have
    achieved."

    The Report notes that public response to a
    Federal Register Notice used to prepare the Report continued the "enhanced
    approach to public engagement" instituted last year, with the USTR
    receiving 41 comments (access to these comments is provided at www.regulations.gov, docket
    number USTR-2012-0022).  In addition, 13 witnesses provided testimony at a
    public hearing on February 20, 2013; these witnesses included "representatives
    of foreign governments, industry, and non-governmental organizations"
    (available on the USTR website).

    The Report notes some "positive
    developments" in the past year, including copyright amendments in the
    Bahamas that benefited U.S. copyright holders, and the removal of Brunei
    from the Watch List due to its "significantly increased its focus on IPR
    protection and enforcement in recent years, through substantial and meaningful
    enforcement efforts, including both civil and — for the first time — criminal
    actions."  Also, "Canada
    enacted the long-awaited Copyright Modernization Act in 2012, which, among
    other things, is designed to implement Canada's obligations under the WIPO
    Internet Treaties and address the challenges of copyright piracy in the digital
    age" which garnered U.S. approval, and Israel "enacted a law
    improving its procedures for the publication of patent applications."  China was lauded in the Report for the
    decision by the Supreme People's Court "on the liability of Internet intermediaries
    ('Rules of Supreme Court on Several Issues Concerning the Application of Law in
    Adjudication of Civil Disputes Related to Infringement of Right of Communication
    over Information Networks')."  The
    Report also extolled Russia for developing an "IPR Action Plan" with
    the U.S. directed towards "the areas of greatest mutual concern in IPR
    protection and enforcement," which include enactment of laws for a
    specialized IPR court and amendments to the Russian criminal code "to
    revise criminal thresholds for copyright piracy."  Panama, the Philippines,
    Taiwan and Turkey were also noted for positive measures adopted by their
    governments in 2012.

    Several initiatives were also
    mentioned.  As in the 2012 Report, these included the Trans-Pacific
    Partnership Agreement, between the U.S. and Australia, Brunei Darussalam,
    Chile, Malaysia, New Zealand, Peru, Singapore, and Vietnam, and in addition,
    Canada, Mexico, and Japan; the Transatlantic Trade and Investment Partnership
    between the U.S. and the EU; actions by the World Trade Organization in support
    of IP rights; the Anti-Counterfeiting Trade Agreement (ACTA) between the U.S. and
    Australia, Canada, Japan, South Korea, Mexico, Morocco, New Zealand, Singapore,
    with Japan becoming the first signatory to deposit its instrument of acceptance;
    bilateral and regional initiatives, including free trade agreements and Trade
    and Investment Framework Agreements; and the USTR Trade Preference Program
    Reviews such as the Generalized System of Preferences (GSP) program relating to
    Russia, Lebanon, and Uzbekistan, and regional programs including the Caribbean
    Basin Economic Recovery Act (CBERA).  Finally, the Representative "looks
    forward to continuing engagement with trading partners in bilateral, regional,
    and multilateral fora to improve the global IPR environment"; including
    the U.S.-EU Summit, and in the Asia Pacific Economic Cooperation (APEC) forum,
    and the Organization for Economic Cooperation and Development (OECD).

    The Report contains a section on "best
    practices" among U.S. trading partners, including "encourage[ing]
    trading partners to work with the United States to develop mutually agreed-upon
    action plans to advance the protection and enforcement of IPR,"
    specifically noting the "action plan" with Russia.  Cooperation
    between governments is also mentioned, as well as "innovative mechanisms
    that enable government and private sector rights holders to voluntarily donate
    or license IPR on mutually-agreed terms and conditions."  These include the use of existing IPR to
    advance policy goals and innovation, specific examples of which are the
    Medicines Patent Pool under the auspices of the World Health Organization and
    the WIPO Re:Search Consortium among the U.S., Brazil and South Africa.

    There is a section of the Report again this
    year regarding "capacity building efforts" that relate to "opportunities
    for the U.S. Government to work closely with trading partners to address [IPR]
    concerns."  These efforts are described in the Report as being
    directed to "building stronger, more streamlined, and more effective
    systems for the protection and enforcement of IPR," which seems to include
    an effort to encourage U.S. trading partners to enact criminal penalties for
    IPR infringement.  The Report documents the efforts of the USPTO's Global
    Intellectual Property Academy (GIPA) to provide training ("9,217 foreign
    IP officials from 130 countries through 140 separate programs") as well as
    programs administered by other U.S. government agencies (including the USPTO's
    Office of Policy and External Affairs; the International Trade Administration;
    the Bureau of Customs and Border Protection; the Commercial Law Development
    Program and programs in law enforcement administered by the Departments of
    Justice and Homeland Security).

    A significant part of the Report focuses
    on "trends" in counterfeiting and copyright piracy, as it has in
    other years.  This area "continue[s] on a global
    scale," according to the Report, "involving the mass
    production and far-reaching sales of a vast array of fake goods, including
    counterfeit semiconductors, medicines, health care products, food and
    beverages, automobile parts, such as air bags, aircraft parts, apparel and
    footwear, toothpaste, shampoos, razors, electronics, batteries, chemicals,
    sporting goods, motion pictures, and music."  The Report recites a "[s]ustained
    growth in piracy of copyrighted products in virtually all formats," which "offer
    enormous profits and little risk."  Online sales of counterfeit goods
    "will soon surpass the volume of such goods sold" in physical
    markets, which raise "difficulties" for IPR enforcement.  Also
    noted is an increase in legitimate businesses, such as courier services,
    enlisted to deliver infringing goods, as well as the practice of producing the
    goods and the counterfeit labels separately, specifically citing Canada and
    Vietnam for such practices.  There is also the emergence of "Media Box
    piracy," defined as a situation "whereby 'boxes,' often with
    capability to play high definition content, are loaded with large quantities of
    pirated works.  These boxes may be sold with preloaded content, but can later
    have new content uploaded for a relatively low fee.  Boxes may be purchased
    online, with the user's chosen content, and delivered via postal service, or
    may have online capabilities allowing consumers to download infringing content
    from the Internet or through downloadable apps.  This problem has been reported
    in China, Indonesia, Malaysia, Taiwan, Thailand, and Vietnam."

    The Report calls for "[s]tronger and
    more effective criminal and border enforcement" to reverse these
    trends.  Another "growing" problem is counterfeit
    pharmaceuticals, either final drug product or active pharmaceutical ingredients
    (API); Brazil, China, India, Indonesia, Lebanon, Peru, and Russia are cited as
    countries where the former type of counterfeiting is a problem and China is
    cited as being a "major source" of counterfeit APIs.

    Another section of the Report is concerned
    with digital piracy, particularly over the Internet, which is "a
    significant concern in many U.S. trading partners."  The "increased
    availability of broadband Internet connections around the world . . . has []
    made the Internet an extremely efficient vehicle for disseminating
    copyright-infringing products, replacing legitimate markets for rights holders,"
    according to the Report.  Piracy is a "significant"
    concern, with "[u]nauthorized retransmission of live sports telecasts over
    the Internet" being singled out as "a growing problem."  New
    technologies, including media boxes as discussed above, are also recognized to
    be a problem, with "U.S. copyright industries also report[ing] growing
    problems with piracy using mobile telephones, tablets, flash drives, and other
    mobile technologies."  Further
    mentioned are the "emergence of private servers, which permit "cloud-based
    entertainment software" to have access to such unauthorized servers "to
    play copyrighted video games that are made available through hacked software
    and/or circumvention of the rights holders' technological protection measures."  In this regard, the Report specifically calls
    out SlySoft, "a company headquartered and operating in Antigua, which
    developed and sells a program called 'Any DVD HD' enabling the user to defeat
    the encryption technology embedded in Blu-ray Discs that prevents unauthorized
    reproduction and distribution," operating despite an Antiguan law
    prohibiting "manufacture or import for sale or rental any such
    circumvention device."  Despite
    cooperation between the Antiguan government and a "consortium of
    electronic manufacturers, software companies, and motion picture studios that
    developed these technological protection measures," progress on changing
    Antiguan law is deemed "slow" in the Report.

    The Report asserts that the U.S. "will
    work with its trading partners to combat these growing problems," and
    urges U.S. trading partners to "adequately implement the WIPO Internet Treaties."  The Report specifically recites a list of trading partners that includes Argentina,
    Belarus, Brazil, Chile, China, Colombia, India, Indonesia, Italy, Mexico,
    Philippines, Romania, Russia, Spain, Switzerland, Taiwan, Thailand, Turkey,
    Ukraine, Venezuela, and Vietnam in this regard, and Switzerland is "strongly
    encourage[d] . . . to combat online piracy vigorously."

    Trade secrets and forced technology
    transfer are identified as problems in "a wide variety of industry sectors"
    that include "information and communication technologies, services,
    biopharmaceuticals, manufacturing, and environmental technologies."  The
    threat of trade secret misappropriation is "increasing," particular
    with regard to electronic espionage.  Particularly noted in the Report in this regard is China, with trade secret
    theft involving "departing employees, failed joint ventures, cyber
    intrusion and hacking, and misuse of information submitted to government
    entities for purposes of complying with regulatory obligations," with
    remedies in China being "difficult to obtain."  "Chinese actors are the world's most
    active and persistent perpetrators of economic espionage," according to
    the U.S. National Counterintelligence Executive, with recent evidence
    indicating that "actors affiliated with the Chinese military and Chinese
    Government have systematically infiltrated the computer systems of over one
    hundred U.S. companies and stolen hundreds of terabytes of data, including all
    forms of trade secrets, such as proprietary technology, manufacturing
    processes, and confidential business information."

    The Report cited a publication by the
    U.S. Intellectual Property Enforcement Coordinator on February 20, 2013 of "Administration
    Strategy on Mitigating the Theft of U.S. Trade Secrets," which "highlights
    U.S. efforts to combat the theft of trade secrets that could be used by foreign
    governments or companies to gain an unfair economic advantage by harming U.S.
    innovation and creativity."  These
    include:

    • "Focusing diplomatic efforts to
    protect trade secrets overseas;
    • Promoting voluntary best practices by
    private industry to protect trade secrets, including information security,
    physical security, and human resources policies;
    • Enhancing domestic law enforcement
    operations, especially through the activities of the Department of Justice,
    Federal Bureau of Investigations, Department of Defense, and the National IPR
    Coordination Center;
    • Improving domestic legislation to protect
    against trade secret theft, [and]
    • Conducting public awareness campaigns
    and stakeholder outreach to encourage all stakeholders to be aware of the
    dangers of trade secret theft."

    The Report also notes that "threat of
    trade secret theft is not the only way that foreign actors may seek to
    undermine U.S. commercial advantages," and urges U.S. trading partners to "eject
    trade-distortive policies," which include:

    • Requiring the transfer of technology as
    a condition for allowing access to a market, or for allowing a company to
    continue to do business in the market;
    • Directing state-owned enterprises in
    innovative sectors to seek non-commercial terms from their foreign business
    partners, including with respect to the acquisition and licensing of IPR;
    • Failing to effectively enforce IPR,
    including patents, trademarks, trade secrets, and copyrights, thereby allowing
    firms to gain competitive advantages from their misappropriation or
    infringement of another's IPR;
    • Failing to take meaningful measures to
    prevent or deter cyber intrusions;
    • Requiring use of, or providing
    preferences to, products or services in which IPR is either developed or owned
    locally, including with respect to government procurement;
    • Manipulating the standards development
    process to create unfair advantages for domestic firms, including with respect
    to the terms on which IPR is licensed;
    • Requiring unnecessary disclosure of
    confidential business information for regulatory approval, or failing to
    protect such information.

    As it has for the past few years, the
    Report contains a section on "Intellectual Property and Health Policy,"
    again specifically mentioning the 2001 Doha Declaration on the TRIPS
    Agreement.  The Report states that the Declaration "recognized the
    gravity of the public health problems afflicting many developing and
    least-developed countries, especially those resulting from HIV/AIDS,
    tuberculosis, malaria, and other epidemics," and that the U.S. "respects
    a trading partner's right to protect public health and, in particular, to
    promote access to medicines for all, and supports the vital role of the patent
    system in promoting the development and creation of new and innovative
    lifesaving medicines."  Accordingly, the Report states that the U.S. "respects
    our trading partners' rights to grant compulsory licenses in a manner
    consistent with the provisions of the TRIPS Agreement, and encourages its
    trading partners to consider ways to address their public health challenges
    while maintaining intellectual property systems that promote investment,
    research, and innovation."  The U.S.
    "strongly supports" the WTO General Council Decision on the
    Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement
    and Public Health.  The Report, in a
    section relating to "pharmaceutical and medical device innovation"
    cites "the policies of several developed trading partners, including
    Finland, Germany, Greece, Hungary, Italy, Korea, New Zealand, Poland, Portugal,
    Romania, Spain, Turkey, and Taiwan, on issues related to innovation in the
    pharmaceutical sector and other aspects of health care goods and services."  The U.S. is "seeking to establish or
    continue dialogues with relevant trading partners to address these and other
    sectoral concerns, and encourage a common understanding on questions related to
    innovation in the pharmaceutical and medical device sectors," specifically
    regarding China in this regard.

    The Report contains in a final section a
    review of U.S. activities in the WTO to resolve disputes with countries such as
    China and the EU over trade issues.

    Section II of Report is a detailed,
    country-by-country discussion for each country on the Priority Watch List and
    the Watch List, relating to the activities (or lack thereof) of each country
    that results in placement of that country on these lists.

    As it has for the past several years (and
    across otherwise very different Administrations), the U.S. Trade Representative
    Report provides insights into both the concerns of U.S. IP rights holders and
    the Administration's intentions to work with, cajole, coerce, or threaten other
    countries to increase protection for IP rights of U.S. IP rights
    holders.  The Report seems to revert to earlier attempts, generally no more
    than partially successful, by the U.S. and other Western governments to
    implement international trade treaties designed to increase IP rights
    protection.  It remains to be seen if that approach is continued in next
    year's Report, or if U.S. trade policy will continue to swing through the
    pendulum of the carrot or the stick regarding international intellectual
    property rights enforcement.

    For additional information regarding this and other related topics, please see:

    • "U.S. Trade Representative Issues 2012 Special 301 Report," May 1, 2012
    • "U.S. Trade Representative Releases Special 301 Report on Global IPR," May 4, 2011
    • "U.S. Trade Representative Releases Special 301 Report on Global IPR," May 19, 2010
    • "New Administration, Same Result: U.S. Trade Representative's Section 301 Report," May 6, 2009
    • "Congressmen Criticize U.S. Trade Representative over Special 301 Report," July 1, 2008
    • "U.S. Continues Efforts to Protect Patent Rights Abroad," April 29, 2008

  • By Josh Bosman

    Mayo ClinicIn March, the U.S. Patent and Trademark Office
    issued U.S. Patent No. 8,401,801, entitled "Methods for
    Selecting Medications."  The '801 patent, which is assigned to the Mayo Foundation for Medical
    Education and Research, contains claims that share some similarities with the claims in U.S. Patent No.
    6,680,302, which was licensed to Prometheus Laboratories, Inc., and which was at issue in Mayo Collaborative Services v. Prometheus Laboratories, Inc.

    The claimed methods of the '801 patent include obtaining a biological
    sample from a patient and determining the patient's genotype for a panel of
    genes.  Then, based on the genotype for
    the panel of genes, a clinician would select a psychotropic medication for
    the patient, which according to the patent, provides a safe method to avoid
    potentially dangerous side effects.  The
    genes of interest in the '801 patent include at least three cytochrome P450
    genes and a serotonin transporter gene.  These genes are known to be important for drug metabolism and
    neurotransmission, respectively, and when examined individually or collectively, may be
    correlated to a patient's sensitivity or resistance to a given medication.

    A specific example of a gene of interest in the patent is
    the P450 CYP2D6, a gene with many known alleles corresponding to increased or
    decreased drug metabolizing activity.  For example, the CYP2D6*4 allele results in a truncated version of the
    gene's protein that does not have catalytic activity.  Therefore, a patient with the CYP2D6*4 allele
    would be determined to be a poor metabolizer and assigned to an appropriate
    medication profile that provides medications that are acceptable for use or
    medications to be used with caution under close monitoring.  By determining a patient's genotype for the
    panel of genes claimed, a practitioner can use the methods of the invention to
    anticipate side effects to a medication and allow a clinician to avoid a number
    of medications a patient may not tolerate.

    The two independent method claims recite a long list of
    genes and alleles to be examined in step (1) and an even longer list of
    medications to select from based on the patient's genotype in step (3).  Abridged versions of claims 1 and 2 recite (with emphasis added):

    1.  A method of administering an antidepressant medication
    to a patient in need thereof comprising:
        (1)  determining the patient[']s genotype
    for a panel of genes comprising the following: . . .
        (2)  assigning a metabolic phenotype to
    the patient based on the genotype of the cytochrome P450 genes in (1), wherein
    the metabolic phenotype is selected from poor (P), intermediate (I), and
    extensive (E), and said phenotype is assigned based upon the number of functional
    alleles for each cytochrome P450 gene as follows: P=no fully functional alleles and either one or no partially
    functional alleles, I=either one fully functional allele and a non-functional
    allele or two partially functional alleles, and E=either one fully functional allele and one partially
    functional allele or two fully functional alleles; and
        (3)  administering to the patient an
    antidepressant medication selected from the group consisting of: . . . .

    2.  A method of administering an antidepressant medication to a patient in need thereof comprising:
        (1)  determining the patients genotype for following panel of genes: . . .
        (2)  assigning a metabolic phenotype to the patient based on the genotype of the cytochrome P450 genes in (1), wherein the metabolic phenotype is selected from poor (P), intermediate (I), and extensive (E), and said phenotype is assigned based upon the number of functional alleles for each cytochrome P450 gene as follows: P=either two partially functional alleles or two increased functional alleles, I=either one fully functional allele and a partially functional allele or one fully functional allele and an increased functional allele, and E=either one partially functional allele and one increased functional allele or two fully functional alleles; and
        (3)  administering to the patient an antidepressant medication selected from the group consisting of: . . . .

    As at least two dozen alleles are to be tested for a given
    patient, and the list of potential medications to be administered in claim 2 is three pages long.  The '801 patent also includes claims directed to methods that "further compris[e] receiving, in a computer system, the patients genotype for the panel of genes, said computer system comprising a database, wherein said database comprises a plurality of antidepressant medication profiles," and "[a] non-transitory computer readable medium containing executable instructions that when executed cause a processor to perform operations comprising: (a) receiving a patient's genotype for a panel of genes . . . (b) assigning a metabolic phenotype to the patient based on the genotype of the cytochrome P450 genes in (1) . . .  and (c) outputting a list of medications suitable for administering to the patient . . . ."

  • By Donald Zuhn

    USPTO Modifies After Final
    Consideration Pilot Program

    USPTO SealEarlier this month, the
    U.S. Patent and Trademark Office published a notice in the Federal Register (78
    Fed. Reg. 29117
    )
    regarding modifications to the After Final Consideration Pilot Program
    (AFCP).  The AFCP, which was implemented
    in April 2012, provides examiners with a limited amount of non-production time
    — three hours for utility and reissue applications — to consider responses
    filed following a final rejection (see
    "USPTO to Assess After Final
    Consideration Pilot Program
    ").  When the program was originally implemented,
    the Office indicated that when an examiner determines that "the nature and
    extent of the amendments or arguments presented in the response can be fully
    considered within the limited amount of time authorized by the [AFCP],"
    the examiner should consider the after final response, and when the examiner
    determines otherwise, the examiner "should treat the response according to
    current practice, without non-production time authorized."

    In implementing the original
    AFCP, the Office described six "limited situations [in which] further
    amendments or arguments may be considered" under the AFCP:

    1.  The amendment places the application
    in condition for allowance by canceling claims or complying with formal
    requirement(s) in response to objection(s) made in the final office action.
    2.  The amendment
    places the application in condition for allowance by rewriting objected-to
    claims in independent form.
    3.  The amendment
    places the application in condition for allowance by incorporating limitations
    from objected-to claims into independent claims, if the new claim can be
    determined to be allowable with only a limited amount of further consideration
    or search.
    4.  The amendment can
    be determined to place the application in condition for allowance with only a
    limited amount of further search or consideration, even if new claims are added
    without cancelling a corresponding number of finally rejected claims.
    5.  The amendment can
    be determined to place the application in condition for allowance by adding new
    limitation(s) which require only a limited amount of further consideration or
    search.
    6.  The response comprises
    a perfected 37 CFR 1.131 or 37 CFR 1.132 affidavit or declaration (i.e. a new
    declaration which corrects formal defects noted in a prior affidavit or
    declaration) which can be determined to place the application in condition for
    allowance with only a limited amount of further search or consideration[.]

    The Office's notice
    regarding the modified program, otherwise known as the After Final
    Consideration Pilot Program 2.0 (AFCP 2.0), indicates that there are three main
    differences between the original AFCP and the AFCP 2.0:  (1) an applicant must file a request to
    participate in the AFCP 2.0; (2) a response after final rejection under the AFCP
    2.0 must include an amendment to at least one independent claim; and (3) when a
    response does not result in a determination that all pending claims are in
    condition for allowance, the examiner will request an interview with the applicant
    to discuss the response.  The notice also
    specifies that the requirements for participating in the AFCP 2.0 are:

    (1) a transmittal form that requests
    consideration under AFCP 2.0 (the Office suggests that applicants use form
    PTO/SB/434
    );
    (2) a response under 37 CFR
    1.116, including an amendment to at least one independent claim that does not
    broaden the scope of the independent claim in any aspect;
    (3) a statement that the
    applicant is willing and available to participate in any interview initiated by
    the examiner concerning the accompanying response (according to the notice, "willing
    and available" means that the applicant is able to schedule the interview within
    ten (10) calendar days from the date the examiner first contacts the applicant);
    (4) any necessary fees (e.g., a request filed more than three
    months after the mailing of a final rejection must include the appropriate fee
    for an extension of time under 37 C.F.R. § 1.136(a)); and
    (5) the required papers
    must be filed via the EFS-Web.

    The AFCP 2.0 took effect on
    May 19, 2013, and the pilot program will run until September 30, 2013.  The Office notes that the AFCP 2.0 is
    intended "to reduce pendency by reducing the number of Requests for
    Continued Examination (RCE) and encouraging increased collaboration between the
    applicant and the examiner to effectively advance the prosecution of the application."


    USPTO Announces Patent for
    Humanity Winners

    P4hLast month, the U.S.
    Department of Commerce announced
    the winner of the USPTO Patents for Humanity pilot program.  The Patents for Humanity pilot program, which
    was launched in February 2012, is a competition recognizing patent owners and
    licensees who address global challenges in health and standards of living.  The competition was divided into four
    categories:  medical technology (with
    separate subcategories for medicines
    & vaccines and diagnostics & devices), food and nutrition, clean
    technology, and information technology. 
    Winners received accelerated processing of select matters at the USPTO
    in addition to recognition for their work. 
    The 2012 winners were as follows:

    Medical – Medicines &
    Vaccines


    Gilead Sciences, for
    making HIV drugs available to the world's poor using a network of generics
    manufacturers in Asia and Africa.

    University of California, Berkeley, for developing research and license agreements to
    provide a lower-cost, more reliable way to produce anti-malarial compounds.

    Medical – Diagnostics &
    Devices


    SIGN Fracture Care International, for distributing low-cost fracture implants to
    speed healing in developing world hospitals.
    • Becton Dickinson (BD), for creating a fast, accurate TB diagnosis
    machine and placing 300 systems in 22 High Burden Countries.

    Food & Nutrition

    DuPont Pioneer, for
    developing an improved strain of sorghum fortified with more protein and
    vitamins for use in sub-Saharan Africa.
    • Intermark Partners Strategic Management LLP, for extracting edible
    protein and vitamins from waste rice bran in Latin America.

    Clean Tech
    • Procter & Gamble, for distributing a small chemical packet
    which removes impurities and contaminants from drinking water and has purified
    nearly 5 billion liters worldwide.
    • Nokero, for delivering solar light bulbs and phone chargers for
    off-grid villages through local entrepreneurs.

    Information Tech

    Sproxil, Inc, for
    deploying a system to identify counterfeit drugs with an ordinary cell phone in
    sub-Saharan Africa.
    • Microsoft Corporation, for providing machine learning tools that
    allow health researchers to better analyze large data sets.

  • By Kevin E. Noonan

    "The
    name of the game is the claim." — Judge Giles Sutherland Rich

    Federal Circuit SealMuch has and will continue to be written
    about the Federal Circuit's en banc decision in CLS Bank Int'l v. Alice Corp. last week, and most of the commentary has
    and will be critical of the path the court took in arriving at its per curiam decision affirming the District Court's determination that the system, method, and computer-readable
    media claims fall within a judicially created exception to the broad scope of
    patent-eligible subject matter under Section 101.  The decision establishes without doubt that
    Section 101 jurisprudence has been broken by the Supreme Court's return to its
    subjective, non-statutory approach exemplified in Benson v. Gottschalk and Parker v. Flook, first in Bilski v. Kappos
    and then in full flower in Mayo v.
    Prometheus
    .  These decisions swing
    the pendulum from Congressional determinations of patent-eligibility to the
    Court's "we know it when we see it" standard that is not only
    directly contrary to the Congressional mandate that created the Federal Circuit
    but also contrary to the Constitutional basis for the Court's review of actions
    by Congress regarding patents.  Specifically, no one with any knowledge of patent law can seriously
    argue that the Court's recent forays in finding exceptions to patent
    eligibility in any way "promote[s] the Progress . . . of the useful Arts."

    CLSBut the decision also illustrates another
    fracture among the Federal Circuit judges that cannot be laid at the Supreme
    Court's doorstep and that in its own way is just as contrary to the statutory
    scheme and to almost two centuries of U.S. patent law.  That is the practice of
    not limiting the inquiry to the language of the claims, but to disregard or
    ignore express claim language in an effort to ascertain "what the inventor
    has invented."  While this tendency
    has many antecedents — including the Supreme Court's Section 101 meanderings
    but also in the Federal Circuit's application of the written description
    requirement and the rubric that the claims should be interpreted in view of the
    specification — it has surfaced frankly in other Federal Circuit decisions, most
    notably in Retractable Techs., Inc. v. Becton, Dickinson & Co., and in the opinions expressed concurrent with the Court's decision
    not to rehear the case en banc.

    Retractable TechnologiesIn the Retractable
    Technologies
    case, Retractable Technologies sued Becton Dickinson for
    infringing claims of U.S. Patent Nos. 5,632,733;
    6,090,077;
    and 7,351,224.  These patent claims were directed to syringes configured to retract the needle
    into the body of the syringe after use, to reduce the likelihood of
    needle-stick injury.  The claim term at issue was "body,"
    specifically whether the term should be construed to be limited to single-piece
    versus multiple piece embodiments.  The District Court construed "body"
    as "a hollow outer structure that houses the syringe's components,"
    and concluded that the term "body" was not limited to a one-piece
    structure.

    The Federal Circuit reversed, in a
    decision by Judge Lourie joined by Judge Plager and (in part) by Chief Judge
    Rader.  The panel reversed the District Court with regard to meaning of "body,"
    finding that the term should be limited to a one-piece structure.  The
    panel found that the claim language was not
    determinative, and disclosure in the specification supported its one-piece body
    construction.  Specifically, the majority based its decision on the specification,
    which described the claimed invention as comprising a one-piece body.  In addition, all the figures illustrated
    syringes comprising a one-piece body, and the specification disparaged prior
    art syringes made of multiple piece bodies.  Moreover, there was no
    disclosure of a multiple piece syringe body in specification.  In
    reversing the District Court's construction, the majority said:

    There is a fine line between construing
    the claims in light of the specification and improperly importing a limitation
    from the specification into the claims.  In reviewing the intrinsic record
    to construe the claims, we strive to capture the scope of the actual invention, rather than strictly limit the
    scope of claims to disclosed embodiments or allow the claim language to become
    divorced from what the specification conveys is the invention.

    (citations omitted, emphasis added)

    Judge Plager filed a concurring opinion
    expanding on this theme, saying that "the claims cannot go beyond the actual invention that entitles the
    inventor to a patent
    " and that "the [patentee's] obligation [was]
    to make full disclosure of what is actually
    invented
    , and to claim that and nothing more" (emphasis added).  Chief Judge Rader, dissenting-in-part, argued
    the primacy of the claim language, and that it is impermissible to read
    limitations from the specification into the claims.

    These disagreements regarding both the
    proper claim construction here and the proper method for performing claim
    construction generally also arose in the Federal Circuit's decision not to
    grant en banc review.  Two dissents were filed in the Court's
    decision not to hear the claim construction decision en banc:  one
    by Judge Moore, joined by Chief Judge Rader, and another by Judge O'Malley. 
    Judge Moore's dissent characterized claim construction as "the single most
    important event in the course of a patent litigation."  However, the
    Federal Circuit's rules for making claim construction determinations remain "ill-defined
    and inconsistently applied," even by the Court in her view.  While
    citing commentators to support this conclusion, this dissent focused on the
    question at issue in Retractable Technologies and, according to Judge
    Moore, a question that arose generally from a deficiency in the Court's
    application of the law:  where to draw the "fine line" between "construing
    the claims in light of the specification and improperly importing a limitation
    from the specification into the claims."  Her dissent contended that
    this
    was the case to consider the issues of "the role of the
    specification in construing the claims and whether deference should be given to
    the district court in the claim construction process."

    Judge Moore relied principally on Phillips v. AWH Corp.,
    415 F.3d 1303, 1312 (Fed. Cir. 2005) (en banc), and the "bedrock
    principle" that "the claims of a patent define the invention to which
    the patentee is entitled the right to exclude."  She discounted the
    concerns voiced by the Retractable Technologies majority, including that
    "the metes and bounds of what the inventor claims extend beyond what he
    has invented or disclosed in the specification."  In that case, the
    question would be one of validity rather than claim construction, she stated,
    and it is not the role of the court to "tailor the claim language to the
    invention disclosed."  Citing Phillips, her dissent relied on
    the mantra that the "plain meaning" of the clams controls (and the
    dissent voiced surprise that this question was not resolved in Phillips). 
    Judge Moore stated her (stringent) standard for the relationship between the
    claims and the specification:  "the specification cannot be used to
    narrow a claim term — to deviate from the plain and ordinary meaning — unless the inventor acted as his own
    lexicographer or intentionally disclaimed or disavowed claim scope,"
    citing Phillips and Teleflex, Inc. v. Ficosa N. Am. Corp.,
    299 F.3d 1313, 1327 (Fed. Cir. 2002)(emphasis added).  Any
    deviation from this procedure should be applied narrowly, in her opinion, and
    specifically, her dissent opined that the choice of an overbroad term may
    affect validity but should not be considered for claim construction. 
    Following a detailed recitation of the facts and legal principles enunciated in
    Phillips, the dissent contrasted the majority decision in Phillips
    with the panel decision here:  in the absence of "disclaimer or
    special lexicography," the plain meaning standard must be applied. 
    And the evidence, according to this dissent, failed to support a claim limited
    to single-body embodiments.

    Judge Moore identified the problem with
    the panel decision with particularity:

    The error in Retractable is
    the majority's attempt to rewrite the claims to better conform to what it
    discerns is the "invention" of the patent instead of construing the
    language of the claim.  Indeed, the majority candidly explained that its
    construction, limiting "body" to a one-piece body, "is required
    to tether the claims to what the specifications indicate the inventor actually
    invented."

    (emphasis in
    original
    )

    While agreeing that the specification and
    claims must comply with the requirements of 35 U.S.C. § 112, her dissent stated
    simply that the Court "does not rewrite claims"; Retractable
    Technologies
    was not a
    case, Judge Moore contended, where "the majority is choosing between two
    equally plausible plain meanings and adopting the one that comports with the
    disclosure in the specification."  Rather, that case was illustrative
    that there is "a fundamental split within the court as to the meaning of Phillips
    and Markman as well as the proper approach to claim interpretation." 
    That was enough to convince Judge Moore and Chief Judge Rader that claim
    construction required reconsideration by the court en banc.  Judge
    Moore also wrote that the Retractable Technologies case had a procedural
    posture that would permit the court to set forth the extent to which the "mongrel
    practice" of claim construction would permit or require deference to a
    district court's factual determinations under Markman v.Westview Instruments, Inc.,
    517 U.S. 370, 378 (1996).

    When considered in this light, some of the
    sentiments expressed by Judge Lourie's "concurring" opinion in CLS Bank Int'l can be
    appreciated as more than just acquiescence to a perceived Supreme Court mandate
    to reign in a "patent-happy" USPTO.  Examples of the propensity to focus on what
    was "invented," rather than what is claimed, include the "description"
    of the invention as:

    [A] computerized trading platform
    used for conducting financial transactions in which a third party settles
    obligations between a first and a second party so as to eliminate "counterparty"
    or "settlement" risk . . . .  Settlement risk refers to the risk
    to each party in an exchange that only one of the two parties will actually pay
    its obligation, leaving the paying party without its principal or the benefit
    of the counterparty's performance.  Alice's patents address that risk by
    relying on a trusted third party to ensure the exchange of either both parties'
    obligations or neither obligation.

    As well as the opinion's discussion of the
    relevant Supreme Court rubrics:

    Where bona fide § 101 concerns
    arise, however, it is important at the outset to identify and define whatever
    fundamental concept appears wrapped up in the claim so that the subsequent
    analytical steps can proceed on a consistent footing.  . . .  In short, one cannot meaningfully
    evaluate whether a claim preempts an abstract idea until the idea supposedly at
    risk of preemption has been unambiguously identified.

    With the pertinent abstract idea
    identified, the balance of the claim can be evaluated to determine whether it
    contains additional substantive limitations that narrow, confine, or otherwise
    tie down the claim so that, in practical terms, it does not cover the full
    abstract idea itself.

    Even computer-readable medium claims
    cannot stand under this analysis ("under § 101 we must look past drafting
    formalities and let the true substance of
    the claim
    guide our analysis").

    This approach, which Judge Lourie terms
    the "inventive concept" approach, may be consistent with recent
    musings by the Supreme Court on the philosophical bases for patent eligibility,
    but it is in stark contrast with what Judge Moore in Retractable Technologies
    recognized was a "bedrock principle," i.e., first interpreting the
    claims consistent with the specification and prosecution history, because only
    then can the particular questions mandated by the Supreme Court — whether the
    claims implicate a law of nature, natural phenomenon or abstract idea, whether
    the claims completely preempt any implicated law of nature, natural phenomenon
    or abstract idea, or whether the claims "merely embody, use, reflect, rest
    upon, or apply those fundamental tools" be answered.

    The application of these principles is not
    lost on the dissenting members of the Court, including Chief Judge Rader who
    writes directly to this point in his "additional observations" as
    well as in his concurring-in-part, dissenting-in-part opinion where he was
    joined by Judges Linn, Moore, and O'Malley.  The Chief Judge, as a former Congressional staffer to Senator Orin
    Hatch, has written before about the importance of courts relying on the
    language of the statute in rendering their opinions (such as in Merck v. Integra and the Hatch-Waxman
    Act) and he does so again here, explicating the legislative history and
    interdependence of Sections 101, 102, and 103 of the 1952 Patent Act (in the
    process emphasizing that Congress had relegated the "inventiveness"
    question, fruit of prior Supreme Court decisions, to Section 103; indeed, even
    the Court itself has recognized that Congress was "merely" codifying this
    requirement, as noted, inter alia, in
    Graham v. John Deere).  In doing so, he rebuts Judge Lourie's
    concurring opinion but also the "less than pellucidly clear" language
    in Bilski and the outright inapt
    language in Mayo, which most clearly
    introduces these concepts back into the Section 101 analysis contrary to
    Congressional intent.  Indeed, Chief Judge
    Rader recognizes the danger in the application of judicial subjectivity in
    Judge Lourie's (and the Mayo)
    approach:

    Any claim can be stripped down,
    simplified, generalized, or paraphrased to remove all of its concrete
    limitations, until at its core, something that could be characterized as an
    abstract idea is revealed . . . .  A court cannot go hunting for
    abstractions by ignoring the concrete, palpable, tangible limitations of the
    invention the patentee actually claims.

    The Chief Judge states his case succinctly
    in his "Additional Reflections" to the court's en banc decision:

    When all else fails, consult the
    statute!

    And for evidence that all else
    has failed, I need only recite Bilski v.
    Kappos
    , 130 S. Ct. 3218 (2010), Mayo
    Collaborative Servs. Inc. v. Prometheus Labs., Inc.
    , 132 S. Ct. 1289
    (2012), Ass'n for Molecular Pathology v.
    U.S. Patent & Trademark Off
    ., 689 F.3d 1303 (Fed. Cir. 2012), cert
    granted in part, 133 S. Ct. 694 (2012), MySpace,
    Inc. v. GraphOn Corp
    ., 672 F.3d 1250 (Fed. Cir. 2012), Dealertrack, Inc. v. Huber, 674 F.3d 1315 (Fed. Cir. 2012), and Classen Immunotherapies, Inc. v. Biogen IDEC,
    659 F.3d 1057 (Fed. Cir. 2011), and this list can and will go on and grow.

    And the remedy is the same:  consult the
    statute!

    And more specifically (and invoking Giles
    Sutherland Rich, the only patent jurist the Supreme Court deigns to consider
    worthy of its recognition), the Chief Judge writes:

    And what about "exceptions"
    like natural laws and natural phenomena?  Of course, these are universal
    constants created, if at all, only by God, Vishnu, or Allah.  But, for
    perspective, even gravity is not a natural law in Einsteinian theory, but a
    symptom of a curved universe.  Einstein posited the speed of light as the only
    true natural constant.  Thus, in context, equating the personalized medicinal
    effect of a human-created pharmaceutical in patients of different metabolic
    rates and genetic makeups with the speed of light (or even gravity) is only
    possible in a netherworld of undefined judicial insights.  Moreover, to inject
    the patentability test of "inventiveness" into the separate statutory
    concept of subject matter eligibility makes this doctrine again "the
    plaything of the judges who, as they became initiated into its mysteries,
    delighted to devise and expound their own ideas of what it meant; some very
    lovely prose resulting."  Giles S. Rich, Principles of Patentability, 28
    Geo. Wash. L. Rev. 393, 404 (1960).

    Among other things, Judge Rich was
    remarkably prescient.

    Paul Scofield, as Sir Thomas More, recites
    a speech in A Man for All Seasons
    that is apropos to Judge Rader's point.  Speaking about God and the devil, the dialog reads as follows:


    William RoperAlice More
    :  Arrest him!

    More:  Why, what has he
    done?

    Margaret More:  He's bad!

    More:  There is no law
    against that.

    William Roper (at right):  There is!  God's law!

    More:  Then God can
    arrest him.

    Alice:  While you talk, he's
    gone!

    More:  And go he should,
    if he was the Devil himself, until he broke the law!

    Roper:  So now you'd give
    the Devil benefit of law!

    More:  Yes.  What would
    you do?  Cut a great road through the law to get after the Devil?

    Roper:  I'd cut down every
    law in England to do that!

    Moore
    And when the last law was down, and the Devil turned round on
    you — where would you hide, Roper, the laws all being flat?  (He leaves him)  This
    country's planted thick with laws from coast to coast — man's laws, not God's — and
    if you cut them down — and you're just the man to do it — d'you really think you
    could stand upright in the winds that would blow then?

    The Supreme Court, in its recent focus on
    patent eligibility, is like Roper, believing that the importance of getting the
    amount of patent eligibility "just right" is important enough to
    ignore the law (at least that portion of the law that mandates that claims are
    what sets forth the metes and bounds of an invention), at all costs.  Judge Rader and those members of the Federal
    Circuit who recognize the folly in this endeavor have, at least, this reliance
    on the law to guide them, when other members of the Federal Circuit seem to have lost
    their way in the fog of recent Supreme Court jurisprudence.

  • By Sherri Oslick

    Gavel About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

    Fresenius Kabi USA LLC v. Dr.
    Reddy's Laboratories Ltd. et al.

    1:13-cv-00925; filed May 23,
    2013 in the District Court of Delaware

    • Plaintiff:  Fresenius Kabi
    USA LLC
    • Defendants:  Dr. Reddy's
    Laboratories Ltd.; Dr. Reddy's Laboratories Inc.

    Infringement of U.S. Patent
    Nos. 5,714,520 ("Propofol Compostion [sic] Containing Edetate,"
    issued February 3, 1998), 5,731,355 ("Pharmaceutical Compositions of
    Propofol and Edetate," issued March 24, 1998), 5,731,356 ("Pharmaceutical
    Compositions of Propofol and Edetate," issued March 24, 1998) and
    5,908,869 ("Propofol Composition Containing Edetate," issued June 1,
    1999) following a Paragraph IV certification as part of Dr. Reddy's filing of
    an ANDA to manufacture a generic version of Fresenius' Diprivan® (propofol injectable
    emulsion, used for the induction and maintenance of general anesthesia and
    sedation in certain patient populations). 
    View the complaint here.


    Purdue Pharma L.P. et al. v.
    PAR Pharmaceutical, Inc.

    1:13-cv-03374; filed May 17,
    2013 in the Southern District of New York

    • Plaintiffs:  Purdue Pharma
    L.P.; P.F. Laboratories, Inc.; Purdue Pharmaceuticals L.P.; Grunenthal GmbH
    • Defendant:  PAR
    Pharmaceutical, Inc.

    Infringement of U.S. Patent
    Nos. 8,337,888 ("Pharmaceutical Formulation Containing Gelling Agent,"
    issued December 25, 2012) and 8,309,060 ("Abuse-Proofed Dosage Form,"
    issued November 13, 2012) following a Paragraph IV certification as part of Par's
    filing of an ANDA to manufacture a generic version of Purdue Pharma's
    OxyContin® (controlled release oxycodone hydrochloride, used to treat
    pain).  View the complaint here.


    Purdue Pharma L.P. et al. v.
    Amneal Pharmaceuticals, LLC

    1:13-cv-03372; filed May 17,
    2013 in the Southern District of New York

    • Plaintiffs:  Purdue Pharma
    L.P.; P.F. Laboratories, Inc.; Purdue Pharmaceuticals LLC
    • Defendant:  Amneal
    Pharmaceuticals, LLC

    Infringement of U.S. Patent
    No. 8,337,888 ("Pharmaceutical Formulation Containing Gelling Agent,"
    issued December 25, 2012) following a Paragraph IV certification as part of Amneal's
    filing of an ANDA to manufacture a generic version of Purdue Pharma's
    OxyContin® (controlled release oxycodone hydrochloride, used to treat
    pain).  View the complaint here.

  • CalendarMay 29, 2013 – AIA and Patent Due Diligence Understanding the AIA Impact and Best Practices for
    the Due Diligence Process
    (Strafford) – 1:00 – 2:30 pm
    (ET)

    May 30, 2013 – Harmonization of USPTO Ethical Standards in
    the Post-AIA Era
    (McDonnell
    Boehnen Hulbert & Berghoff LLP) – 10:00 – 11:15 am (CT)

    May 30, 2013 – CLS Opinions: What to
    Do Now
    (Intellectual Property Owners Association) – 2:00 – 3:00 pm (ET)

    June
    5-7, 2013 – Advanced Forum on Biosimilars (American Conference
    Institute) – New York, NY

    June 9-11, 2013 – IP Business Congress (Intellectual Asset
    Management) – Boston, MA

    June 11, 2013 – Preventing Chinese Trade Secret
    Theft: The Obama Administration's Strategy on Mitigating the Theft of U.S.
    Trade Secrets
    (McDonnell
    Boehnen Hulbert & Berghoff LLP) – 10:00 to 11:15 am
    (CT)

    June 12, 2013 – Post-Grant Patent Proceedings Before the PTAB (Strafford) – 1:00 – 2:30 pm (EDT)

    June 12-14, 2013 – Fundamentals of Patent Prosecution
    2013: A Boot Camp for Claim Drafting & Amendment Writing
    (Practising
    Law Institute) – New York, NY

    July 15-16, 2013 – Global Patenting Strategy and Practice (American Conference
    Institute) – New
    York, NY

    July 15-19, 2013 – Patent Law Summer
    Intensive
    (Benjamin N. Cardozo School of Law) – New York, NY

    June 25-26, 2013 – Maximising
    Pharma Patents
    (C5 (UK)) – London, England

    July
    10-12, 2013 – Fundamentals of Patent Prosecution
    2013: A Boot Camp for Claim Drafting & Amendment Writing
    (Practising
    Law Institute) – San Francisco, CA

    July 31 to August 2, 2013 – Advanced Patent Law Seminar (Chisum Patent Academy) – Seattle, WA

    August 5-7, 2013 – Advanced Patent Law Seminar (Chisum Patent Academy) – Seattle, WA

    ***Patent Docs is a media partner of this conference or CLE

  • IPO #2The
    Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled
    "CLS Opinions: What to
    Do Now" on May 30, 2013 beginning at 2:00 pm (ET).  A panel consisting of Michael Chernoff, Director of Legal Services, Patent Operations for
    Accenture; Andrew Hirshfeld, Deputy Commissioner for Patent Examination Policy
    at the U.S. Patent and Trademark Office; and J. Michael Jakes of Finnegan, Henderson, Farabow, Garrett &
    Dunner, LLP will provide their thoughts on the following topics:

    • Bolstering the specification of a patent to follow
    the line of reasoning in RCT and Ultramercial;
    • Including as much detail as possible on how the
    computer implements the idea, even though that's not a guarantee the claims
    will be found eligible;
    • Focusing on Judge Lourie's rejection of the idea
    that subject matter eligibility is a threshold question that a judge must always
    consider first, and his emphasis that all issued patents are presumed to be
    valid; and
    • Whether the Federal Circuit's rulings in prior
    software patent cases, such as Cybersource and Dealertrack, are
    precedential.

    The
    registration fee for the webinar is $120 (government and academic rates are
    available upon request).  Those
    interested in registering for the webinar can do so here.

  • New York #3American Conference
    Institute (ACI) will be holding its Advanced Summit on Global Patenting Strategy and Practice on July 15-16, 2013 in New
    York, NY.  ACI faculty will help
    attendees:

    • Develop a global
    patenting strategy to protect the commercial embodiment of your product in
    critically important markets around the world;
    • Determine the
    impact of patent harmonization efforts on your ability to protect your IP in
    foreign jurisdictions;
    • Review and understand
    the standards for patentability, filing requirements, claim construction, and
    obviousness or inventive step in major markets like the EU, China, Japan,
    Korea, and more;
    • Contrast the
    opposition procedures utilized in the U.S. post-America Invents Act, at the
    EPO, in China, and elsewhere;
    • Utilize the ITC
    as a forum for litigating international patent disputes; and
    • Craft effective
    strategies for protecting trade secrets in numerous countries, whether they
    have robust IP protections in place or not.

    BrochureIn particular,
    ACI's faculty will offer presentations on the following topics:

    • Understanding the Importance of Developing a
    Global Strategy for Your Patent Portfolio 
    — to be presented in part by Patent
    Docs
    author Dr. Kevin Noonan
    • An Alignment of Interests: Determining the
    Impact of Patent Harmonization Efforts on IP Protection
    • Devising
    Effective Strategies for Working with Inventors in Foreign Jurisdictions
    • A Review of
    Guidelines for Patentability and Novelty in Different Patent Office
    • Comparing Claim Drafting and Construction
    Standards in Important Jurisdictions
    • Exploring Obviousness and Inventive Step
    Concepts Around the World
    • Analyzing Written
    Description and Specification Requirements Across Different Patent Regimes
    • Comparing and Contrasting Opposition
    Proceedings in the US and EU
    • Navigating the "Ins" and
    "Outs" of Opposition Practice Across the World
    • Using the International Trade Commission
    (ITC) as a Venue for Global Patent Conflicts
    • Crafting Effective Strategies for Protecting
    Trade Secrets in Multiple Jurisdictions
    • Addressing the Challenges Presented by
    Compulsory Licensing Provisions Abroad

    Two post-conference
    workshops will be held on July 17, 2013. 
    The first, entitled "Mastering
    the Foreign Patent Law and Regulatory Requirements for Life Sciences Companies
    in a Global Context," will be offered from 9:00 am to 12:00 pm.  The second, entitled "The Interactive Working Group Session:
    Negotiating the Obstacles and Challenges Associated with Patenting a Product in
    Numerous Jurisdictions," will be offered from 1:30 pm to 4:30 pm.

    The agenda for the Global Patenting Strategy and Practice
    conference can be found here,
    and additional information about the post-conference workshops can be found
    here.  A complete brochure for this conference,
    including an agenda, detailed descriptions of conference sessions, list of
    speakers, and registration form can be obtained here.

    ACI - American Conference InstituteThe registration
    fee for the conference is $2,295 (conference alone), $2,895 (conference and one
    workshop), or $3,295 (conference and both workshops).  Those registering by June 21, 2013 will
    receive a $200 discount.  Patent
    Docs
    readers who reference the discount code "PD200" will receive $200 off the current price tier when registering.  Those
    interested in registering for the conference can do so here,
    by e-mailing CustomerService@AmericanConference.com, by calling 1-888-224-2480,
    or by faxing a registration form to 1-877-927-1563.

    Patent Docs is a media partner of ACI's Global
    Patenting Strategy and Practice conference.

  • Strafford #1Strafford
    will be offering a webinar/teleconference entitled "Post-Grant Patent Proceedings Before the PTAB"
    on June 12, 2013 from 1:00 – 2:30 pm (EDT). 
    Scott A. McKeown and Greg H. Gardella of Oblon Spivak McClelland Maier
    & Neustadt will discuss the new post-grant patent practice and offer best
    practices for counsel to either patentees or third parties in inter partes review, post-grant review,
    and covered business method challenges. 
    The panel will review the following questions:

    • How has post-grant practice been transformed since
    the America Invents Act?
    • What are the best practices for the new post-grant
    review and inter partes review?
    • What are the strategic approaches for counsel
    dealing with covered business method patent challenges?

    The
    registration fee for the webinar is $297 ($362 for registration and CLE
    processing).  Those interested in
    registering for the webinar, can do so here.